A Two-Arm, Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Peginterferon Beta-1a (BIIB017) in Japanese and Caucasian Adult Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2015
Price : $35 *
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 19 Aug 2014 Status changed from active, no longer recruiting to completed.
- 10 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
- 16 Nov 2013 New trial record